Results 111 to 120 of about 6,250 (152)
Letrozole vs. Clomiphene Citrate for Infertility in Polycystic Ovarian Syndrome [PDF]
, 2018 Purpose To determine if letrozole is an equal or better alternative to clomiphene citrate for infertility treatment in PCOS patients. Literature Review Letrozole was found to have higher ovulation rates, fewer twin pregnancies/more single births, higher ...
Potratz, Kailey
core
This is the original dataset from the clinical study investigating letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive, platinum-resistant, recurrent epithelial ovarian cancer after failure of second-line ...
Yang, Yiting
core +1 more source
Letrozole and ovarian hyperstimulation syndrome: Retrospective cross-sectional study
Background: Recently, letrozole has been used to prevent moderate to severe ovarian hyperstimulation syndrome (OHSS) in assisted reproductive technology cycles due to its estrogen-reducing and androgen-increasing effects on the ovaries, affecting ...
Arabian, Sahereh +3 more
core +1 more source
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy [PDF]
Annals of Oncology, 2021 Background: Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET).
Patrick Neven +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Steroid Biochemistry and Molecular Biology, 2003
Recent clinical trials indicate that the third-generation aromatase inhibitors may be more effective than tamoxifen as first line endocrine therapy in ER+ metastatic breast cancer in postmenopausal women. This review will focus exclusively on the pharmacology of the non-steroidal inhibitor letrozole.
Mitch Dowsett +2 more
exaly +3 more sources
Recent clinical trials indicate that the third-generation aromatase inhibitors may be more effective than tamoxifen as first line endocrine therapy in ER+ metastatic breast cancer in postmenopausal women. This review will focus exclusively on the pharmacology of the non-steroidal inhibitor letrozole.
Mitch Dowsett +2 more
exaly +3 more sources
Expert Opinion on Drug Metabolism & Toxicology, 2010
Aromatase is an enzyme which converts adrenal androgens to estrogens in postmenopausal women. Given the importance of estrogens in breast cancer growth, aromatase inhibitors are used to treat breast cancer in different settings. This review focuses on letrozole, a third generation aromatase inhibitor, encompassing pharmacodynamic and pharmacokinetic ...
Silvia, Dellapasqua, Marco, Colleoni
openaire +3 more sources
Aromatase is an enzyme which converts adrenal androgens to estrogens in postmenopausal women. Given the importance of estrogens in breast cancer growth, aromatase inhibitors are used to treat breast cancer in different settings. This review focuses on letrozole, a third generation aromatase inhibitor, encompassing pharmacodynamic and pharmacokinetic ...
Silvia, Dellapasqua, Marco, Colleoni
openaire +3 more sources